Abstract
Background: Previously, we showed that the Zinc finger-containing transcription factor ZNF424 inhibits p21 transcription, which has been widely associated with various cancers. However, because the roles of ZNF424 in tumorigenesis have not been characterized, we correlated ZNF424 expression with tumorigenesis in lung cancer.
Results: The present immunohistochemical analyses show significantly lower ZNF424 expression levels in 43 of 60 lung cancer tissues compared with adjacent tissues. Moreover, flow cytometry assays indicated that overexpression of ZNF424 induces apoptosis in A549 human lung carcinoma cells, and overexpression of ZNF424 significantly increases numbers of G1 phase cells and decreases numbers of S phase cells, suggesting that ZNF424 inhibits proliferation. Western Blot analyses show that overexpression of ZNF424 decreases protein expression levels of the mitogen-activated protein kinase (MAPK) signaling proteins P-P38 and P-ERK in A549 cells.
Conclusion: These are the first data to associate ZNF424 with tumorigenesis and demonstrate an inhibitory role in lung cancer, indicating the potential of ZNF424 expression as a diagnostic marker of lung tumorigenesis.
Keywords: ZNF424, lung cancer, apoptosis, MAPK pathway.
Current Molecular Medicine
Title:ZNF424 Induces Apoptosis and Inhibits Proliferation in Lung Carcinoma Cells
Volume: 18 Issue: 2
Author(s): W. Liu, W. Yuan, X. Li, J. Zhuang, X. Mo, G. Dai, Y. Wang, J. Chen, Y. Wan, Y. Li, X. Zhu, Y. Chen, S. Luo, Z. Jiang, Y. Shi, F. Chen, L. Cao, X. Ye, X. Fan*, P. Zhu*, K. Zhang*X. Wu*
Affiliation:
- The Center for Heart Development, State Key Laboratory of Development Biology of Freshwater Fish, Key Laboratory of MOE for Development Biology and Protein Chemistry, The National & Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, Hunan 410081,China
- Department of Cardiac Surgery, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510100,China
- The National Clinical Research Center for Geriatrics, Xiangya Hospital of Central South University, Changsha, Hunan 410008,China
- The Center for Heart Development, State Key Laboratory of Development Biology of Freshwater Fish, Key Laboratory of MOE for Development Biology and Protein Chemistry, The National & Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, Hunan 410081,China
Keywords: ZNF424, lung cancer, apoptosis, MAPK pathway.
Abstract: Background: Previously, we showed that the Zinc finger-containing transcription factor ZNF424 inhibits p21 transcription, which has been widely associated with various cancers. However, because the roles of ZNF424 in tumorigenesis have not been characterized, we correlated ZNF424 expression with tumorigenesis in lung cancer.
Results: The present immunohistochemical analyses show significantly lower ZNF424 expression levels in 43 of 60 lung cancer tissues compared with adjacent tissues. Moreover, flow cytometry assays indicated that overexpression of ZNF424 induces apoptosis in A549 human lung carcinoma cells, and overexpression of ZNF424 significantly increases numbers of G1 phase cells and decreases numbers of S phase cells, suggesting that ZNF424 inhibits proliferation. Western Blot analyses show that overexpression of ZNF424 decreases protein expression levels of the mitogen-activated protein kinase (MAPK) signaling proteins P-P38 and P-ERK in A549 cells.
Conclusion: These are the first data to associate ZNF424 with tumorigenesis and demonstrate an inhibitory role in lung cancer, indicating the potential of ZNF424 expression as a diagnostic marker of lung tumorigenesis.
Export Options
About this article
Cite this article as:
Liu W. , Yuan W., Li X. , Zhuang J. , Mo X. , Dai G. , Wang Y. , Chen J. , Wan Y. , Li Y. , Zhu X. , Chen Y. , Luo S., Jiang Z. , Shi Y. , Chen F. , Cao L. , Ye X. , Fan X. *, Zhu P. *, Zhang K. *, Wu X. *, ZNF424 Induces Apoptosis and Inhibits Proliferation in Lung Carcinoma Cells, Current Molecular Medicine 2018; 18 (2) . https://dx.doi.org/10.2174/1566524018666180705113642
DOI https://dx.doi.org/10.2174/1566524018666180705113642 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Olive Oil and Cancer Risk: an Update of Epidemiological Findings through 2010
Current Pharmaceutical Design Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery A Review of HPLC Methods Used for Determining the Presence of Meloxicam
Current Pharmaceutical Analysis The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) 18F-Labeled Proteins
Current Pharmaceutical Biotechnology Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Novel Aglycones of Steroidal Glycoalkaloids as Potent Tyrosine Kinase Inhibitors: Role in VEGF and EGF Receptors Targeted Angiogenesis
Letters in Drug Design & Discovery Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Screening of Potential Plant Compounds as Survivin Inhibitors and its Anti-Cancer Efficacy by Molecular Docking
Current Enzyme Inhibition Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review
Current Medicinal Chemistry MDR Reversal by Deprenylated Tetracyclic and Hexacyclic Analogues of N-Acetylardeemin: Confirmation of the Ardeemin Pharmacophore
Letters in Drug Design & Discovery Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets